Trial to Evaluate the Efficacy and Safety of Dapagliflozin in Japanese Type 2 Diabetes Mellitus Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

417

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Dapagliflozin

once daily, 12 weeks

DRUG

Placebo

once daily, 12 weeks

Trial Locations (20)

Unknown

Research Site, Anjyo

Research Site, Bunkyō City

Research Site, Chūōku

Research Site, Daitō

Research Site, Kamagaya

Research Site, Kashiwara

Research Site, Matsuyama

Research Site, Nagoya

Research Site, Naka

Research Site, Nakano

Research Site, Nerima-ku

Research Site, Okinawa

Research Site, Osaka

Research Site, Sapporo

Research Site, Shibuya-ku

Research Site, Shinjyuku-ku

Research Site, Suita

Research Site, Uji

Research Site, Wakayama

Research Site, Yamato

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

AstraZeneca

INDUSTRY